

Long-Term Survival Outcomes After Liver Resection for Binodular Hepatocellular Carcinoma: A Multicenter Cohort Study

MING-DA WANG,^{a,†} CHAO LI,^{a,†} JUN LI,^{a,†} WAN-GUANG ZHANG,^{b,†} WEI-QIN JIANG,^{c,†} JIONG-JIE YU,^{a,†} HAO XING,^{a,†} HAN WU,^{a,†} JUN HAN,^a ZHEN-LI LI,^a XIN-FEI XU,^a TING-HAO CHEN,^d YA-HAO ZHOU,^e WEI-MIN GU,^f HONG WANG,^g YONG-YI ZENG,^h YAO-MING ZHANG,ⁱ TIMOTHY M. PAWLICK,^j WAN YEE LAU,^{a,k} MENG-CHAO WU,^a JIA-MEI YANG,^a FENG SHEN,^a TIAN YANG^a

^aThe 1st Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, People's Republic of China; ^bDepartment of Hepatic Surgery, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, People's Republic of China; ^cCancer Biotherapy Center, First Affiliated Hospital, School of Medicine of Zhejiang University, Zhejiang, People's Republic of China; ^dDepartment of General Surgery, Ziyang First People's Hospital, Sichuan, People's Republic of China; ^eDepartment of Hepatobiliary Surgery, Pu'er People's Hospital, Yunnan, People's Republic of China; ^fThe First Department of General Surgery, the Fourth Hospital of Harbin, Heilongjiang, People's Republic of China; ^gDepartment of General Surgery, Liuyang People's Hospital, Hunan, People's Republic of China; ^hDepartment of Hepatobiliary Surgery, Mengchao Hepatobiliary Hospital, Fujian Medical University, Fujian, People's Republic of China; ⁱThe Second Department of Hepatobiliary Surgery, Meizhou People's Hospital (Huangtang Hospital), Meizhou Hospital to Sun Yat-sen University, Meizhou, People's Republic of China; ^jDepartment of Surgery, Ohio State University, Wexner Medical Center, Columbus, Ohio, USA; ^kFaculty of Medicine, the Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, N.T., Hong Kong SAR

[†]Contributed equally

Disclosures of potential conflicts of interest may be found at the end of this article.

Key Words. Hepatocellular carcinoma • Hepatectomy • Overall survival • Recurrence-free survival • Multicentric origin • Intrahepatic metastasis

ABSTRACT

Background. The long-term prognosis after liver resection for multinodular (≥ 3 nodules) hepatocellular carcinoma (HCC) is generally considered to be unfavorable. However, the role of liver resection for binodular HCC is less investigated.

Subjects, Materials, and Methods. From a multicenter database, consecutive patients who underwent curative-intent liver resection for binodular HCC and without macrovascular invasion between 2003 and 2015 were retrospectively reviewed. Patients' clinical variables as well as perioperative and long-term survival outcomes were analyzed. Univariable and multivariable analyses were performed to identify the risk factors associated with overall survival (OS) and recurrence-free survival (RFS) after curative resection.

Results. Of 263 enrolled patients, the perioperative 30-day mortality and morbidity rates were 1.5% and 28.5%. The 1-, 3-, and 5-year OS and RFS rates were 81.5%, 52.4%, and

39.1% and 57.1%, 35.8%, and 26.6%, respectively. Multivariable Cox-regression analyses identified preoperative alpha-fetoprotein level >400 $\mu\text{g/L}$, tumor size with a sum of two nodules >8 cm, tumor size ratio of large/small nodule >1.5 (asymmetrical proportion), unilateral hemiliver distribution of two nodules, distance of ≤ 3 cm between two nodules, and microvascular invasion in any nodule as independent risk factors associated with decreased OS and RFS.

Conclusion. Liver resection was safe and feasible in patients with binodular HCC, with acceptable perioperative and long-term outcomes. Sum of two tumor sizes, size ratio and distribution, and distance between two nodules were independent risk factors associated with long-term survival outcomes after surgery. These results may guide clinicians to make individualized surgical decisions and estimate long-term prognosis for these patients. *The Oncologist* 2019;24:e730–e739

Implications for Practice: Liver resection was safe and feasible in patients with binodular hepatocellular carcinoma, with acceptable perioperative and long-term outcomes. The sum of two tumor sizes, the size ratio and distribution of the two nodules, and the distance between two nodules were independent risk factors associated with long-term overall survival and recurrence-free survival after liver resection. The results of this study may guide clinicians to make individualized surgical decisions, estimate long-term prognosis, and plan recurrence surveillance and adjuvant therapy for these patients.

Correspondence: Tian Yang, M.D., Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, No. 225, Changhai Rd., Shanghai 200438, People's Republic of China. Telephone: +86 021 81875182; e-mail: yangtianehbh@smmu.edu.cn; or Feng Shen, M.D., Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, No. 225, Changhai Rd., Shanghai 200438, People's Republic of China. Telephone: +86 021 81875005; e-mail: fengshensmmu@gmail.com Received December 19, 2018; accepted for publication April 17, 2019; published Online First on May 24, 2019. <http://dx.doi.org/10.1634/theoncologist.2018-0898>

INTRODUCTION

Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent neoplasm and the third leading cause of cancer-related mortality globally [1, 2]. Survival in patients with HCC is generally poor, with an overall 5-year survival rate of <15%. Liver resection remains the mainstay of curative treatment for HCC, with survival rates ranging from 40% to 70% at 5 years after resection [3, 4]. The bottleneck that limits long-term survival outcomes after liver resection of HCC is the high recurrence rate of up to 60%–70% within 5 years after liver resection. Aggressive pathological characteristics of the initial tumor, including large tumor size, incomplete tumor encapsulation, macroscopic and microscopic vascular invasion, and multinodularity, have been associated with postoperative HCC recurrence, especially early recurrence (<2 years after surgery) and worse long-term overall survival outcomes.

Multinodular HCC may originate from intrahepatic metastasis from a single tumor or multicentric origin from several independent neoplasms [5]. Studies on clonal origin revealed that multinodular HCCs arising from multicentric origin are more likely to benefit from liver resection than those arising from intrahepatic metastasis of a single tumor [6–8]. Actually, at the time of diagnosis of multinodular HCCs, when the HCC nodules are ≥ 3 , the chance of intrahepatic metastasis is much higher than for those of multicentric origin [9, 10]. Therefore, the long-term prognosis after liver resection in patients with multinodular HCC of ≥ 3 nodules is generally unfavorable [11–13]. Our previous studies have demonstrated that HCC nodules ≥ 4 , total tumor nodule diameter > 8 cm, and a ratio of largest/smallest tumor nodule diameter > 6 were independently associated with significantly worse long-term survival outcomes after liver resection for multinodular HCC of ≥ 3 nodules [14, 15]. Binodular HCC (with two tumor nodules) are uncommon at first diagnosis. However, the clonal origin and the long-term prognosis after liver resection for binodular HCC have been underinvestigated.

Based on a large multicenter database, the aims of this study are (a) to evaluate the clinical patterns as well as the perioperative and long-term survival outcomes and (b) to elucidate independent risk factors associated with long-term recurrence and survival after curative liver resection of binodular HCC. This study may provide useful guidance for individual surgical decision-making, planning recurrence surveillance, and adjuvant therapy.

SUBJECTS, MATERIALS, AND METHODS

Patient Selection

A multicenter database of consecutive patients who underwent curative-intent liver resection for binodular HCC from January 2003 to December 2015 at eight Chinese hospitals was retrospectively reviewed. The eight hospitals included the Eastern Hepatobiliary Surgery Hospital, Tongji Hospital, Ziyang First People's Hospital, Pu'er People's Hospital, Liuyang People's Hospital, Fourth Hospital of Harbin, Mengchao Hepatobiliary Hospital, and Meizhou People's Hospital. In this study, binodular HCC was defined as two HCC nodules of any

size but > 2 cm from each other in distance, or two HCC nodules of > 2 cm in size but within 2 cm from each other in distance. The inclusion criteria for this study were patients (a) with binodular HCC confirmed by preoperative imaging and histopathological examination of the resected specimens; (b) who underwent curative liver resection, which was defined as complete resection of all macroscopic tumors with microscopically clear resection margins in the resected specimen (R0 resection); (c) with no macroscopic vascular invasion; (d) without any previous anti-HCC treatment before resection; and (e) who had a complete record on all essential prognostic variables. The exclusion criteria were patients (a) ≤ 18 years of age; (b) with a single nodule or multiple nodules of HCC (≥ 3 nodules) by both preoperative imaging and postoperative histopathological examination; (c) with recurrent HCC; (d) with a combined HCC-cholangiocarcinoma; (e) with macroscopic vascular invasion or who underwent palliative liver resection, that is, microscopically positive (R1 resection) or grossly positive (R2 resection) resection margins, considering that macrovascular invasion and positive margins have the highest risks of long-term prognosis, which would weaken the exposure of the prognostic effects from those tumor characteristics from binodular HCC; (f) who had missing data on essential prognostic variables or follow-up information; and (g) who had an inconsistent nodular number between preoperative imaging and postoperative pathological examination. This study was censored on August 31, 2018. Informed consent for the data to be used for clinical researches was obtained from all the enrolled patients. This study was approved by the Institutional Review Board and Ethics Committee of each of the eight hospitals. Informed consent was obtained from all the enrolled patients, and all analyses were performed in accordance with the ethical guidelines for clinical studies of these involved hospitals.

Clinicopathological Variables

The patients' demographic characteristics included sex, age, diabetes mellitus, history of alcohol intake, preoperative body mass index, and American Society of Anesthesiologists score. The clinicopathological characteristics included etiologies of liver disease, cirrhosis, portal hypertension, Child-Pugh grading and preoperative serum alpha-fetoprotein (AFP) levels within 1 week before surgery, tumor sizes of the two nodules, distribution of the two nodules, distance between the two nodules, microvascular invasion, satellite lesions, and tumor differentiation. Portal hypertension was diagnosed when there was presence of either esophageal varices or splenomegaly with a low platelet count ($\leq 100 \times 10^9/L$). Satellite lesions were defined as tumors of < 2 cm in diameter and located < 2 cm from the main tumor [16]. When two nodules were in the same hemiliver (right or left), it was defined as unilateral hemiliver in distribution; meanwhile, if the two nodules were in different hemilivers or either of the two nodules were at the junction of the right and left hemilivers, this was defined as bilateral hemiliver in distribution.

The operative variables consisted of intraoperative blood loss, intraoperative blood transfusion, extent of hepatectomy, and type of resection. Major hepatectomy involved resection

of three or more Couinaud liver segments, whereas minor hepatectomy involved resection of fewer than three segments. The definition of anatomical resection was based on the Brisbane 2000 Nomenclature of Liver Anatomy and Resections [17], and nonanatomical resection indicated wedge/limited resection.

Perioperative outcomes consisted of perioperative 30-day mortality and morbidity rates. Perioperative mortality was defined as death within 30 days of surgery or before discharge from hospital. Complications that occurred during this period were considered as perioperative morbidity and were classified according to the Clavien-Dindo system [18]. Major morbidity was defined as Clavien-Dindo grade III–IV, whereas minor morbidity was grade I–II.

Follow-Up

Patients were followed up at each of the participating hospitals. The postoperative surveillance strategy for HCC recurrence consisted of a physical examination, serum AFP, and ultrasonography or contrast-enhanced computed tomography (CT) scan or magnetic resonance imaging (MRI) of the chest and abdomen at 2-month intervals for the first 6 months, 3-month intervals thereafter for the next 18 months, and once every 6 months thereafter. Tumor recurrence was defined as appearance of new intra- or extrahepatic tumor nodule(s), with or without a rise in serum AFP level, and the intrahepatic nodules had the typical imaging features of HCC on contrast-enhanced CT or MRI examinations. HCC recurrences were treated with re-resection; transcatheter arterial chemoembolization (TACE); local ablation; radiation; molecular targeted drugs or supportive therapy, depending on the pattern of recurrence; liver functional reserve; and general conditions of the patients. The dates of recurrence, last follow-up, and death during follow-up were recorded.

Statistical Analysis

Patients' clinical variables and perioperative outcomes were summarized using frequencies and percentages for categorical variables and mean \pm SD or median (range) for continuous variables. Categorical variables were compared using the χ^2 test with the Yates correction or Fisher's exact test. Continuous variables were compared using the Student's *t* test or Mann-Whitney ranked *U* test. The cutoff values of the continuous variables were based on either those used commonly in reported studies or the largest Youden index for prognostic prediction. The endpoints of this study were overall survival (OS) and recurrence-free survival (RFS). OS was defined as the interval between the date of operation and the patient's death or last follow-up, and RFS was the interval between the date of operation and the date when HCC recurrence or new tumor occurrence were diagnosed, or between surgery and death or last follow-up for those recurrence-free patients. Kaplan-Meier method and log-rank test were used to estimate and compare the OS and RFS rates. Uni- and multivariable Cox regression analyses were used to identify any independent risk factors associated with decreased OS and RFS after liver resection. The statistical analyses were performed using the SPSS software version 25.0 (SPSS, Chicago, IL). All tests were two-tailed, with a statistically significant *p* value $< .05$.




Figure 1. Selection of the study population.

Abbreviation: HCC, hepatocellular carcinoma.

RESULTS

Clinical Variables and Perioperative Outcomes

During the study period, 263 patients with binodular HCC who underwent curative liver resection were included in the multicenter database. These patients formed the analytic cohort (Fig. 1). There were 236 men (89.7%) and 27 women (10.3%). The perioperative 30-day mortality and morbidity rates were 1.5% and 28.5%, respectively, and the minor and major morbidity rates were 21.3% and 7.2%, respectively.

Using the size ratio of the large/small nodules, the tumors were classified as symmetrical (size ratio ≤ 1.5 , *n* = 91, 34.6%) and asymmetrical (size ratio > 1.5 , *n* = 172, 65.4%) HCCs. The patients' characteristics, operative variables, and perioperative outcomes between these two groups are shown in Table 1. When compared with the symmetrical HCCs, the asymmetrical HCCs had larger tumor sizes of both the large and small nodules, longer distance between the two nodules, a higher percentage of satellite lesions, and a higher rate of minor hepatectomy (all *p* $< .05$). There were no significant differences in the perioperative mortality and morbidity rates (for both minor or major liver resection) between patients with symmetrical and asymmetrical HCCs.

There were 196 patients in the unilateral hemiliver group (74.5%) and 67 in the bilateral hemiliver group (25.5%). Comparisons of the patients' characteristics, operative variables, and perioperative outcomes between these two groups are summarized in supplemental online Table 1. There were no significant differences in almost all the clinical variables and perioperative outcomes between the two groups, except for the distance between the two nodules (mean \pm SD: 3.2 ± 2.8 vs. 7.0 ± 3.8 cm, *p* $< .001$). A representative set of the three-dimensional CT imaging and operative photographs of a 62-year-old male with symmetrical HCCs located in bilateral hemilivers are shown in Figure 2.

Long-Term Outcomes

At a median follow-up of 63.2 months, 193 patients (74.5%) had developed HCC recurrence and 185 patients (71.4%)

Table 1. Comparisons of clinical variables and perioperative outcomes between patients with symmetrical and asymmetrical binodular hepatocellular carcinoma according to size ratio between large/small nodule

Variables	Total (n = 263)	Symmetrical binodular HCC (n = 91)	Asymmetrical binodular HCC (n = 172)	p value
Age, years				
≤60	219 (83.3)	75 (82.4)	144 (83.7)	.788
>60	44 (16.7)	16 (17.6)	28 (16.3)	
Sex				
Male	236 (89.7)	82 (90.1)	154 (89.5)	.884
Female	27 (10.3)	9 (9.9)	18 (10.5)	
Diabetes mellitus	18 (6.8)	4 (4.4)	14 (8.1)	.253
Alcohol intake	45 (17.1)	13 (14.3)	32 (18.6)	.376
Body mass index, kg/m ²				
≤24.0	170 (64.6)	56 (61.5)	114 (66.3)	.444
>24.0	93 (35.4)	35 (38.5)	58 (33.7)	
ASA score				
≤2	240 (91.3)	84 (92.3)	156 (90.7)	.660
>2	23 (8.7)	7 (7.7)	16 (9.3)	
Etiology of liver diseases				
HBV	237 (90.1)	81 (89.0)	156 (90.7)	.399
HCV	6 (2.3)	4 (4.4)	2 (1.2)	
HBV + HCV	3 (1.1)	1 (1.1)	2 (1.2)	
Others	17 (6.5)	5 (5.5)	12 (7.0)	
Preoperative HBV-DNA level (n = 211), IU/mL				
≤2,000	127 (58.1)	49 (57.0)	78 (58.8)	.889
>2,000	94 (41.9)	37 (43.0)	57 (41.2)	
Cirrhosis	203 (77.2)	71 (78.0)	132 (76.7)	.814
Portal hypertension	94 (35.7)	38 (41.8)	56 (32.6)	.139
Child-Pugh grading				
A	239 (90.9)	84 (92.3)	155 (90.1)	.557
B	24 (9.1)	7 (7.7)	17 (9.9)	
Preoperative AFP level, µg/L				
≤400	158 (60.1)	55 (60.4)	103 (59.9)	.930
>400	105 (39.9)	36 (39.6)	69 (40.1)	
Tumor size of larger nodule, cm ^a	6.4 ± 3.9	3.9 ± 2.2	7.7 ± 3.9	<.001
≤5	124 (47.1)	70 (76.9)	54 (31.4)	<.001
>5	139 (52.9)	21 (23.1)	118 (68.6)	
Tumor size of smaller nodule, cm ^a	2.1 ± 1.2	2.7 ± 1.5	2.0 ± 0.9	<.001
≤3	217 (82.5)	67 (73.6)	150 (87.2)	.006
>3	46 (17.5)	24 (26.4)	22 (12.8)	
Distribution of the two nodules				
Unilateral hemiliver	196 (74.5)	65 (71.4)	131 (76.2)	.402
Bilateral hemiliver	67 (25.5)	26 (28.6)	41 (23.8)	
Distance between the two nodules, cm ^a	4.2 ± 3.5	5.5 ± 4.1	3.5 ± 2.9	<.001
≤3	142 (54.0)	32 (35.2)	110 (64.0)	<.001
>3	121 (46.0)	59 (64.8)	62 (36.0)	
Microvascular invasion of any nodule	173 (65.8)	55 (60.4)	118 (68.6)	.184
Satellite lesions of any nodule	166 (63.1)	41 (45.1)	125 (72.7)	<.001
Poor differentiation of any nodule	242 (92.0)	81 (89.0)	161 (93.6)	.191
Incomplete capsule of any nodule	202 (76.8)	65 (71.4)	137 (79.7)	.133

(continued)

Table 1. (continued)

Variables	Total (n = 263)	Symmetrical binodular HCC (n = 91)	Asymmetrical binodular HCC (n = 172)	p value
Intraoperative blood loss, mL				
≤400	124 (47.1)	48 (52.7)	76 (44.2)	.186
>400	139 (52.9)	43 (47.3)	96 (55.8)	
Intraoperative blood transfusion	77 (29.3)	21 (23.1)	56 (32.6)	.108
Extent of hepatectomy				
Major hepatectomy	104 (39.5)	27 (23.1)	77 (48.3)	.017
Minor hepatectomy	159 (60.5)	64 (76.9)	95 (51.7)	
Type of resection				
Anatomical	68 (25.9)	24 (26.4)	44 (25.6)	.889
Nonanatomical	195 (74.1)	67 (73.6)	128 (74.4)	
Perioperative mortality	4 (1.5)	1 (1.1)	3 (1.7)	.999
Perioperative morbidity	75 (28.5)	24 (26.4)	51 (29.7)	.575
Minor morbidity (Clavien grade I–II)	56 (21.3)	17 (18.7)	39 (22.7)	.452
Major morbidity (Clavien grade III–V)	19 (7.2)	7 (7.7)	12 (7.0)	.831

Data are presented as n (%) unless otherwise indicated.

^aValues are mean ± SD.

Abbreviations: AFP, alpha-fetoprotein; ASA, American Society of Anesthesiologists; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus.




Figure 2. A representative set of the three-dimensional computed tomography (CT) imaging and operative photographs of a 62-year-old male with symmetrical HCCs located in bilateral hemilivers. Enhanced CT three-dimensional imaging (**A, D**) of a 62-year-old man shows two large lesions located in Segments 7 and 8 (right liver, tumor size: 12.0 cm) and Segments 3 and 4 (left liver, tumor size: 12.5 cm), respectively. His preoperative alpha-fetoprotein level was 825 ng/mL (normal value: ≤20 ng/mL). This patient underwent curative liver resection for symmetrical large binodular hepatocellular carcinomas (**B, C, E, F**) on October 27, 2015, and was alive and recurrence-free on the last date of follow-up on December 1, 2018.

Table 2. Comparisons of long-term outcomes after curative resection between patients with symmetrical and asymmetrical binodular hepatocellular carcinoma according to size ratio between large/small nodule

Variables	Total (n = 259)	Symmetrical binodular HCC (n = 90)	Asymmetrical binodular HCC (n = 169)	p value
Period of follow-up, months ^a	63.2 ± 3.8	94.2 ± 7.6	47.2 ± 3.9	<.001
Recurrence during the follow-up, n (%)	193 (74.5)	54 (60.0)	139 (82.2)	<.001
Death during the follow-up, n (%)	185 (71.4)	44 (48.9)	141 (83.4)	<.001
Median OS (95% CI), months	39.4 (30.4–48.4)	91.7 (59.6–123.8)	26.8 (22.7–30.9)	<.001
1-year OS rate, %	81.5	94.4	74.6	
3-year OS rate, %	52.4	76.5	40.2	
5-year OS rate, %	39.1	60.9	28.8	
Median RFS (95% CI), months	18.7 (13.8–23.7)	49.6 (25.3–73.9)	10.4 (7.0–13.7)	<.001
1-year RFS rate, %	57.1	78.9	45.6	
3-year RFS rate, %	35.8	61.0	23.1	
5-year RFS rate, %	26.6	47.9	17.5	

^aValues are mean ± SD.

Abbreviations: CI, confidence interval; HCC, hepatocellular carcinoma; OS, overall survival; RFS, recurrence-free survival.

had died. The 1-, 3-, and 5-year OS rates for the entire cohort were 81.5%, 52.4%, and 39.1%, respectively. The corresponding RFS rates were 57.1%, 35.8%, and 26.6%, respectively (supplemental online Fig. 1). The long-term outcomes after curative resection between patients with symmetrical and asymmetrical HCC are listed in Table 2. The postoperative recurrence and death rates of the asymmetrical group were significantly higher than those of the symmetrical group (82.2% vs. 60.0%, $p < .001$, and 83.4% vs. 48.9%, $p < .001$, respectively). The OS and RFS curves for the symmetrical and asymmetrical groups are depicted in Figure 3. The 5-year OS and RFS rates of the asymmetrical group were significantly poorer than those of the symmetrical group (28.8% vs. 60.9%, $p < .001$, and 17.5% vs. 47.9%, $p < .001$, respectively).

The postoperative recurrence and death rates of the unilateral hemiliver group were also significantly higher than those of the bilateral hemiliver group (78.2% vs. 63.4%, $p = .019$, and 75.1% vs. 60.6%, $p = .024$, respectively; supplemental online Table 2). The unilateral hemiliver group had significantly poorer 5-year OS and RFS rates than the bilateral hemiliver group (34.3% vs. 52.6%, $p = .019$, and 21.1% vs. 42.2%, $p = .001$, respectively; supplemental online Fig. 2).

The 5-year OS and RFS rates in patients with a distance of ≤ 3 cm between the two tumor nodules were significantly worse than those in patients with a distance of > 3 cm (20.1% vs. 64.2%, $p < .001$, and 10.0% vs. 50.3%, $p = .001$, respectively; supplemental online Fig. 3).

Univariable and Multivariable Analyses of OS and RFS

Table 3 shows the results of the univariable and multivariable analyses identifying the risk factors associated with OS after curative liver resection for binodular HCC. Multivariable Cox-regression analyses demonstrated that preoperative AFP level > 400 $\mu\text{g/L}$ (hazard ratio [HR], 1.385; 95% confidence interval [CI], 1.028–1.866; $p = .032$), sum of tumor size of the two nodules > 8.0 cm (HR, 1.546; 95% CI, 1.116–2.142; $p = .009$), tumor size ratio of large/small nodule > 1.5 (asymmetrical proportion;

HR, 2.010; 95% CI, 1.403–2.880; $p < .001$), distance between the two nodules ≤ 3 cm (HR, 2.374; 95% CI, 1.687–3.340; $p < .001$), unilateral hemiliver in distribution of the two nodules (HR, 1.846; 95% CI, 1.288–2.644; $p = .001$), and microvascular invasion of any nodule (HR, 1.415; 95% CI, 1.020–1.964; $p = .038$) were independent risk factors of worse OS.

Table 4 depicts the results of the univariable and multivariable Cox-regression analyses identifying risk factors associated with RFS after curative liver resection for binodular HCC. Multivariable Cox-regression analyses demonstrated preoperative AFP level > 400 $\mu\text{g/L}$ (HR, 1.390; 95% CI, 1.043–1.853; $p = .025$), sum of tumor size of the two nodules > 8 cm (HR, 1.534; 95% CI, 1.128–2.085; $p = .006$), tumor size ratio of large/small nodule > 1.5 (asymmetrical proportion; HR, 2.566; 95% CI, 1.788–3.683; $p < .001$), distance between the two nodules ≤ 3 cm (HR, 1.701; 95% CI, 1.209–2.395; $p = .002$), unilateral hemiliver in distribution of the two nodules (HR, 2.648; 95% CI, 1.897–3.697; $p < .001$), microvascular invasion of any nodule (HR, 1.476; 95% CI, 1.080–2.016; $p = .014$), and intraoperative blood transfusion (HR, 1.298; 95% CI, 1.022–1.785; $p = .044$) were independent risk factors of worse RFS.

DISCUSSION

In this multicenter, retrospective cohort study, the clinical patterns as well as perioperative and long-term survival outcomes of 263 patients who underwent curative liver resection for binodular HCC were evaluated. The results showed that patients with binodular HCC had acceptable short- and long-term outcomes with perioperative mortality and morbidity rates of 1.5% and 28.5%, respectively, and 5-year OS and RFS rates of 39.1% and 26.6%, respectively. Multivariable Cox-regression analyses identified preoperative AFP level > 400 $\mu\text{g/L}$, sum of size of the two nodules > 8 cm, asymmetrical proportion (size ratio of large/small nodule > 1.5), distance between the two nodules ≤ 3 cm, unilateral hemiliver in distribution of the two nodules, and microvascular invasion of any nodule as the independent risk factors of decreased OS and RFS after liver resection for binodular HCC. To our knowledge,




Figure 3. The overall survival and recurrence-free survival curves for the symmetrical and asymmetrical groups. Comparisons of overall survival (A) and recurrence-free survival (B) curves between patients with symmetrical and asymmetrical binodular hepatocellular carcinoma.

this is the first study to evaluate the long-term postoperative prognosis and prognostic risk factors exclusively for patients with binodular HCC, which could provide useful guidance for individual surgical decision-making, planning for recurrence surveillance, and advice on adjuvant therapy for these patients.

The Barcelona Clinic Liver Cancer (BCLC) staging classification, as recommended by the European Association for the Study of the Liver and American Association for the Study of Liver Diseases [19], is commonly used in clinical management of patients with HCC. In the BCLC staging, patients with multiple HCC nodules but without macrovascular invasion or extrahepatic spread are classified to be in intermediate stage of disease, except for patients who are within the Milan criteria (≤ 3 nodules that are ≤ 3 cm in diameter). Only TACE is

recommended for these patients. Although HCC with multiple nodules is known to be an adverse prognostic factor, in selected patients, liver resection still provides the best chance of a cure [11, 20]. Whether these simultaneously occurring tumor nodules are the results of intrahepatic metastases from a single initial tumor (“the mother-child type”) or multicentric in origin from several independent neoplasms (“the brother-brother type”) is the key influencing postoperative prognosis after liver resection. When the nodule number is ≥ 3 , the relationship is most likely to be “the mother-child type,” instead of “the brother-brother type.” The greatest difficulty in estimating the relationship is when the number of tumor nodules is two at the time of HCC diagnosis. All the current approaches including genetic mutation detection are inadequate to accurately distinguish the clonal origins of these simultaneous nodules because of the high heterogeneity in the separate tumor nodules [21–23]. In this study, the clinicopathological characteristics of the two tumor nodules were used to study the relationship of the nodules indirectly as well as to evaluate the long-term prognosis after liver resection.

Our previous studies demonstrated that for patients with multiple HCC of ≥ 3 nodules, the size ratio of the large/small nodule was an independent predictor of long-term survival after curative resection [14, 15]. The results of this study also showed that the size ratio of the large/small nodule was independently associated with OS and RFS after curative liver resection for binodular HCC. This size ratio may represent the originality of the two tumor nodules in patients. A small size ratio or a symmetrical proportion of the two nodules represented an increased probability of multicentric separate occurrence (“the brother-brother type”), whereas a large ratio represented an asymmetrical proportion of the two nodules with a higher likelihood of origin from intrahepatic metastasis from an initial tumor (“the mother-child type”). Thus, this variable can be helpful in selecting patients with binodular HCC to get better survival benefits from liver resection [7, 24].

Intrahepatic metastasis is a predominant characteristic that reflects on the high aggressiveness of HCC and provides an explanation for the poor long-term survival outcomes after liver resection for patients with the “mother-child” HCC with multiple nodules. For these patients, even after all gross tumor nodules have been eradicated by resection, micro-metastases are likely to be left in the remaining liver, leading to early HCC recurrence [25, 26]. As intrahepatic metastases of HCC mainly spread through the portal venous system [27, 28], metastatic foci usually spread to the same liver segment, sector, or hemiliver before spreading to the contralateral hemiliver. On the other hand, binodular HCC in different hemilivers are more likely to be “the brother-brother type” with independent clonal origins. Multivariable analyses of our study demonstrated that the OS and RFS rates in patients with bilateral hemiliver distribution of the two tumor nodules were significantly higher than those in patients with unilateral hemiliver distribution of the two tumor nodules. This is inconsistent with the previous view that multiple HCC nodules with bilateral hemiliver involvement were generally not recommended for surgery [29]. Our data demonstrated that bilateral hemiliver tumor distribution undergoing liver resection was safe and efficacious.

Table 3. Univariable and multivariable Cox-regression analyses of overall survival after liver resection for binodular hepatocellular carcinoma

Variables	HR comparison	UV HR (95% CI)	UV <i>p</i> value	MV HR (95% CI)	MV <i>p</i> value ^a
Age	≤60 vs. >60 years	1.042 (0.715–1.519)	.830		
Sex	Male vs. female	1.062 (0.651–1.734)	.809		
Body mass index	≤24.0 vs. >24.0 kg/m ²	1.270 (0.943–1.712)	.116		
Diabetes mellitus	Yes vs. no	1.535 (0.888–2.653)	.125		
Alcohol intake	Ever vs. never	1.223 (0.845–1.770)	.286		
ASA score	≤2 vs. >2	1.183 (0.727–1.925)	.499		
HBV (+)	Yes vs. no	0.864 (0.517–1.444)	.577		
HCV (+)	Yes vs. no	0.982 (0.435–2.218)	.965		
Cirrhosis	Yes vs. no	1.011 (0.716–1.426)	.952		
Portal hypertension	Yes vs. no	1.069 (0.794–1.439)	.660		
Child-Pugh grading	A vs. B	1.662 (1.043–2.650)	.033	NS	.774
Preoperative HBV-DNA level	≤2,000 vs. >2,000 IU/mL	1.373 (1.024–1.840)	.034	NS	.325
Preoperative AFP level	≤400 vs. >400 µg/L	1.698 (1.269–2.274)	<.001	1.385 (1.028–1.866)	.032
Tumor size of larger tumor	≤5 vs. >5 cm	1.576 (1.177–2.109)	.002	NS	.462
Tumor size of smaller tumor	≤3 vs. >3 cm	1.737 (1.111–2.714)	.015	NS	.895
Tumor sizes of the two nodules	≤8 vs. >8 cm	1.580 (1.183–2.110)	.002	1.546 (1.116–2.142)	.009
Size ratio of large/small nodules	Asymmetrical (>1.5) vs. symmetrical (≤1.5)	2.623 (1.866–3.686)	<.001	2.010 (1.403–2.880)	<.001
Distance between the two nodules	≤3 vs. >3 cm	3.359 (2.444–4.616)	<.001	2.374 (1.687–3.340)	<.001
Distribution of the two nodules	Unilateral vs. bilateral	1.521 (1.070–2.163)	.019	1.846 (1.288–2.644)	.001
Microvascular invasion of any nodule	Yes vs. no	1.718 (1.254–2.356)	.001	1.415 (1.020–1.964)	.038
Satellite lesions of any nodule	Yes vs. no	1.414 (1.042–1.919)	.026	NS	.676
Poor differentiation of any nodule	Yes vs. no	1.321 (0.751–2.324)	.334		
Incomplete capsule of any nodule	Yes vs. no	2.725 (1.837–4.044)	<.001	NS	.755
Intraoperative blood loss	≤400 vs. >400 mL	1.461 (1.091–1.955)	.011	NS	.201
Intraoperative blood transfusion	Yes vs. no	2.255 (1.663–3.057)	<.001	NS	.125
Extent of hepatectomy	Major vs. minor	1.424 (1.010–2.007)	.044	NS	.123
Type of resection	Anatomic vs. nonanatomic	0.732 (0.517–1.086)	.118		

Bolded *p* values are statistically significant.

^aVariables with a univariate *p* ≤ .10 were entered in the multivariate Cox regression model.

Abbreviations: AFP, alpha-fetoprotein; ASA, American Society of Anesthesiologists; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; MV, multivariable; NS, not significant; OS, overall survival; UV, univariable.

The distance between the two tumor nodules was another important variable to reflect the biological relationship. A short distance means that the two tumors were close to each other, and they are more likely to be “the mother-child type,” whereas a long distance likely indicates “the brother-brother type.” In the present study, patients with a distance of >3 cm between the two tumor nodules had significantly better OS and RFS rates than those with a tumor distance of ≤3 cm.

In short, binodular HCC with symmetrical proportion, bilateral hemiliver distribution, or a long distance between the two tumor nodules are more likely to synchronously arise from multicentric origin, which can theoretically be regarded as two single “early-stage” HCCs. These tumors responded well to surgical resection (Fig. 2) [24, 30]. On the other hand, binodular HCC with asymmetrical proportion, unilateral hemiliver distribution, or a short distance between the two tumor nodules are

likely to arise from metastasis from a single initial tumor, which is a late stage of HCC with poor response to liver resection.

In fact, in this cohort of patients with resected binodular HCC, a small number of patients still meet Milan Criteria (i.e., the sum of diameter of the two tumors does not exceed 3 cm). For these patients who are suitable for liver transplantation, whether liver transplantation could lead to a better long-term prognosis than liver resection is an interesting topic that needs to be further discussed. Prospective observational studies and even randomized controlled trials are warranted for this issue.

The present study has several limitations. First, this is a retrospective study that has the inherent potential to introduce biases. Second, because all the patients enrolled in this study were submitted to surgical interventions with preserved liver function, and patients with macrovascular

Table 4. Univariable and multivariable Cox-regression analyses of recurrence-free survival after liver resection for binodular hepatocellular carcinoma

Variables	HR comparison	UV HR (95% CI)	UV <i>p</i> value	MV HR (95% CI)	MV <i>p</i> value ^a
Age	≤60 vs. >60 years	1.110 (0.777–1.585)	.568		
Sex	Male vs. female	0.841 (0.545–1.298)	.433		
Body mass index	≤24.0 vs. >24.0 kg/m ²	1.178 (0.887–1.562)	.257		
Diabetes mellitus	Yes vs. no	1.307 (0.771–2.213)	.320		
Alcohol intake	Ever vs. never	1.167 (0.817–1.667)	.397		
ASA score	≤2 vs. >2	1.153 (0.723–1.838)	.551		
HBV (+)	Yes vs. no	1.001 (0.609–1.648)	.996		
HCV (+)	Yes vs. no	1.095 (0.514–2.333)	.814		
Cirrhosis	Yes vs. no	0.765 (0.760–1.452)	.765		
Portal hypertension	Yes vs. no	1.025 (0.772–1.360)	.865		
Child-Pugh grading	A vs. B	1.236 (0.784–1.947)	.362		
Preoperative HBV-DNA level	≤2,000 vs. >2,000 IU/mL	1.366 (1.035–1.803)	.027	NS	.258
Preoperative AFP level	≤400 vs. >400 µg/L	1.718 (1.302–2.265)	<.001	1.390 (1.043–1.853)	.025
Tumor size of larger tumor	≤5 vs. >5 cm	1.603 (1.217–2.110)	.001	NS	.675
Tumor size of smaller tumor	≤3 vs. >3 cm	1.723 (1.154–2.571)	.008	NS	.221
Tumor sizes of the two nodules	≤8 vs. >8 cm	1.535 (1.168–2.016)	.002	1.534 (1.128–2.085)	.006
Size ratio of large/small nodules	Asymmetrical (>1.5) vs. symmetrical (≤1.5)	2.420 (1.783–3.286)	<.001	2.566 (1.788–3.683)	<.001
Distance between the two nodules	≤3 vs. >3 cm	3.517 (2.599–4.760)	<.001	1.701 (1.209–2.395)	.002
Distribution of the two nodules	Unilateral vs. bilateral	1.707 (1.223–2.383)	.001	2.648 (1.897–3.697)	<.001
Microvascular invasion of any nodule	Yes vs. no	1.707 (1.270–2.293)	.001	1.476 (1.080–2.016)	.014
Satellite lesions of any nodule	Yes vs. no	1.426 (1.070–1.901)	.015	NS	.410
Poor differentiation of any nodule	Yes vs. no	1.323 (0.781–2.240)	.298		
Incomplete capsule of any nodule	Yes vs. no	2.615 (1.831–3.736)	<.001	NS	.324
Intraoperative blood loss	≤400 vs. >400 mL	1.255 (0.955–1.649)	.103		
Intraoperative blood transfusion	Yes vs. no	1.998 (1.494–2.673)	<.001	1.298 (1.022–1.785)	.044
Extent of hepatectomy	Major vs. minor	1.677 (1.272–2.211)	<.001	NS	.257
Type of resection	Anatomic vs. nonanatomic	0.739 (0.534–1.024)	.070	NS	.856

Bolded *p* values are statistically significant.

^aVariables with a univariate *p* ≤ .10 were entered in the multivariate Cox regression model.

Abbreviations: AFP, alpha-fetoprotein; ASA, American Society of Anesthesiologists; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; HR, hazard ratio; MV, multivariable; NS, not significant; OS, overall survival; UV, univariable.

invasion were excluded, the data may not represent the entire populations of patients with binodular HCC. Third, the majority of patients had a background of hepatitis B virus infection, which is the predominant etiological factor for HCC in China [31]. The conclusions of this study may not be applied to patients coming from North America and European countries. Fourth, this multicenter study did not allow for the standardization of operative technique in liver resection. Lastly, although the overall sample size of this study was close to 300, the study was still relatively small and did not allow subgroup analyses.

CONCLUSION

The results of the present multicenter cohort study showed that liver resection could be safely performed in patients with

binodular HCC, with acceptable perioperative and long-term outcomes. The sum of two tumor sizes, size ratio, distribution of the two tumor nodules, and the distance between the two tumor nodules were independent risk factors of long-term OS and RFS outcomes after liver resection. The results of this study may guide clinicians to make individualized surgical decision, estimate long-term prognosis, and plan recurrence surveillance and adjuvant therapy for these patients.

ACKNOWLEDGMENTS

This work was supported in part by National Natural Science Foundation of China (No. 81702334, 81472284, 81802350, and 81672699), Shanghai Pujiang Program (No. 16PJD004), and Shanghai Sailing Program (17YF1424900). The funding sources had no role in the design and conduct of the study; collection,

management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

AUTHOR CONTRIBUTIONS

Conception/design: Ming-Da Wang, Chao Li, Jia-Mei Yang, Feng Shen, Tian Yang

Provision of study material or patients: Ting-Hao Chen, Ya-Hao Zhou, Wei-Min Gu, Hong Wang, Yong-Yi Zeng, Yao-Ming Zhang, Jia-Mei Yang

Collection and/or assembly of data: Ming-Da Wang, Chao Li, Jun Li, Wan-Guang Zhang, Wei-Qin Jiang, Jiong-Jie Yu, Hao Xing, Han Wu, Jun Han, Zhen-Li Li, Xin-Fei Xu, Tian Yang

Data analysis and interpretation: Ming-Da Wang, Chao Li, Timothy M. Pawlik, Meng-Chao Wu, Wan Yee Lau, Tian Yang

Manuscript writing: Ming-Da Wang, Wan Yee Lau, Feng Shen, Tian Yang

Final approval of manuscript: Wan Yee Lau, Meng-Chao Wu, Jia-Mei Yang, Feng Shen, Tian Yang

DISCLOSURES

The authors indicated no financial relationships.

REFERENCES

1. Siegel R, Ma J, Zou Z et al. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9–29.
2. Gerbes A, Zoulim F, Tilg H et al. Gut roundtable meeting paper: Selected recent advances in hepatocellular carcinoma. *Gut* 2018;67:380–388.
3. Bruix J, Gores GJ, Mazzaferro V. Hepatocellular carcinoma: Clinical frontiers and perspectives. *Gut* 2014;63:844–855.
4. Chan AC, Poon RT, Ng KK et al. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. *Ann Surg* 2008;247:666–673.
5. Chianichiano P, Pezhouh MK, Kim A et al. Distinction of intrahepatic metastasis from multicentric carcinogenesis in multifocal hepatocellular carcinoma using molecular alterations. *Hum Pathol* 2018;72:127–134.
6. Nakano S, Haratake J, Okamoto K et al. Investigation of resected multinodular hepatocellular carcinoma: Assessment of unicentric or multicentric genesis from histological and prognostic viewpoint. *Am J Gastroenterol* 1994;89:189–193.
7. Yasui M, Harada A, Nonami T et al. Potentially multicentric hepatocellular carcinoma: Clinicopathologic characteristics and postoperative prognosis. *World J Surg* 1997;21:860–864; discussion 864–865.
8. Cheung ST, Chen X, Guan XY et al. Identify metastasis-associated genes in hepatocellular carcinoma through clonality delineation for multinodular tumor. *Cancer Res* 2002;62:4711–4721.
9. Lin YW, Lee HS, Chen CH et al. Clonality analysis of multiple hepatocellular carcinomas by loss of heterozygosity pattern determined by chromosomes 16q and 13q. *J Gastroenterol Hepatol* 2005;20:536–546.
10. Tsuda H, Oda T, Sakamoto M et al. Different pattern of chromosomal allele loss in multiple hepatocellular carcinomas as evidence of their multifocal origin. *Cancer Res* 1992;52:1504–1509.
11. Ng KK, Vauthey JN, Pawlik TM et al. Is hepatic resection for large or multinodular hepatocellular carcinoma justified? Results from a multi-institutional database. *Ann Surg Oncol* 2005;12:364–373.
12. Zhao WC, Zhang HB, Yang N et al. Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma. *World J Gastroenterol* 2012;18:3272–3281.
13. Wada H, Eguchi H, Noda T et al. Selection criteria for hepatic resection in intermediate-stage (BCLC stage B) multiple hepatocellular carcinoma. *Surgery* 2016;160:1227–1235.
14. Yang P, Qiu J, Li J et al. Nomograms for pre- and postoperative prediction of long-term survival for patients who underwent hepatectomy for multiple hepatocellular carcinomas. *Ann Surg* 2016;263:778–786.
15. Yang P, Wu D, Xia Y et al. A prognostic scoring system for patients with multiple hepatocellular carcinomas treated by hepatectomy. *Ann Surg Oncol* 2015;22:826–833.
16. Yang T, Lu JH, Lau WY et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: A Propensity Score Matching Analysis. *J Hepatol* 2016;64:583–593.
17. Pang YY. The Brisbane 2000 terminology of liver anatomy and resections. *HPB* 2000; 2:333–39. *HPB (Oxford)* 2002;4:99; author reply 99–100.
18. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205–213.
19. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. *Lancet* 2018;391:1301–1314.
20. Ishizawa T, Hasegawa K, Aoki T et al. Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma. *Gastroenterology* 2008;134:1908–1916.
21. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: Epidemiology and molecular carcinogenesis. *Gastroenterology* 2007;132:2557–2576.
22. Llovet JM, Zucman-Rossi J, Pikarsky E et al. Hepatocellular carcinoma. *Nat Rev Dis Primers* 2016;2:16018.
23. Schulze K, Nault JC, Villanueva A. Genetic profiling of hepatocellular carcinoma using next-generation sequencing. *J Hepatol* 2016;65:1031–1042.
24. Utsunomiya T, Shimada M, Taguchi KI et al. Clinicopathologic features and postoperative prognosis of multicentric small hepatocellular carcinoma. *J Am Coll Surg* 2000;190:331–335.
25. Imamura H, Matsuyama Y, Tanaka E et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. *J Hepatol* 2003;38:200–207.
26. Yang SL, Luo YY, Chen M et al. A systematic review and meta-analysis comparing the prognosis of multicentric occurrence and vs. intrahepatic metastasis in patients with recurrent hepatocellular carcinoma after hepatectomy. *HPB (Oxford)* 2017;19:835–842.
27. Sakon M, Nagano H, Nakamori S et al. Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: Analysis based on tumor hemodynamics. *Arch Surg* 2002;137:94–99.
28. Sakon M, Ogawa H, Fujita M et al. Hepatic resection for hepatocellular carcinoma based on tumor hemodynamics. *Hepatol Res* 2013;43:155–164.
29. Ruzzenente A, Capra F, Pachera S et al. Is liver resection justified in advanced hepatocellular carcinoma? Results of an observational study in 464 patients. *J Gastrointest Surg* 2009;13:1313–1320.
30. Matsumoto Y, Fujii H, Matsuda M et al. Multicentric occurrence of hepatocellular carcinoma: Diagnosis and clinical significance. *J Hepatobiliary Pancreat Surg* 2001;8:435–440.
31. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. *Gastroenterology* 2012;142:1264–1273.e1.



See <http://www.TheOncologist.com> for supplemental material available online.